Skip to content
ClinCalc Pro
Menu
Dual-Mechanism Opioid Analgesic (MOR + NRI)

Tapentadol

Brand names: Palexia, Palexia SR

Tapentadol is a centrally acting opioid analgesic used for moderate to severe acute and chronic pain, including musculoskeletal and post-operative pain.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It combines mu-opioid receptor agonism with noradrenaline reuptake inhibition, providing analgesia through two complementary mechanisms.

Prescribing in practice

  • As an opioid it can cause respiratory depression, dependence and overdose, with risk increased by concomitant benzodiazepines, alcohol or other CNS depressants.
  • Because of its noradrenergic action it should be used with caution with serotonergic and other monoaminergic drugs owing to the risk of serotonin syndrome, and it is contraindicated with or close to monoamine oxidase inhibitors.
  • It can lower the seizure threshold and should be used cautiously in patients with epilepsy or a history of seizures.

Monitoring

Monitor pain relief, sedation, respiratory status and for signs of tolerance or dependence during treatment.

Counselling the patient

  • Do not drink alcohol while taking this medicine, and tell your team about any sedatives you use.
  • It may cause drowsiness and affect your ability to drive or operate machinery.
  • Do not stop suddenly after prolonged use; the dose should be reduced gradually.

Evidence & guidelines

Tapentadol is an established option for moderate to severe pain in current prescribing references.

Reference: MHRA Drug Safety Update 2013; SPC Palexia SR; CONIFER trial; NICE CG173; NICE NG59; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.